Investment
Features
FeesSafety
Academy
More
Pluang+

Gladstone offers four monthly dividend streams from loans, buyouts, industrial leases, and farmland with varying risk and yield.

Market News
19 Oct 2026
24/7 Wall Street
View Source
Bullish
Gladstone offers four monthly dividend streams from loans, buyouts, industrial leases, and farmland with varying risk and yield.

Gladstone's management team in Virginia provides investors with four distinct monthly dividend payments sourced from loans to small companies, buyout equity, industrial property leases, and farmland revenue. Each dividend stream has different risk profiles and payout safety: Gladstone Capital and Gladstone Investment (BDCs) pay from loan interest, while Gladstone Commercial and Gladstone Land (REITs) pay from rent and crop revenue. Yields range from about 6% to over 9%, with coverage and risks varying by segment. Investors benefit from diversified income streams but should monitor credit stress in loans and seasonal income fluctuations in farmland. The unified ex-dividend date is October 23, 2026.

Gladstone's dividend lineup is the subject, offered here with Pluang's Financials sector market data for context. For readers following Financials, of 142 priced US stocks on Pluang, 67 rose and 39 fell today. Notable movers include Valley National Bancorp (VLY) at USD 13.00, up 2.69%, KB Financial Group (KB) at USD 122.00, up 2.68%, and CleanSpark Inc (CLSK) at USD 8.61, up 2.50%, as of Oct 19, 2026 17:41 WIB.

More News

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...

Others
Neutral
1 hour ago
EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint announced that its DURAVYU treatment for wet age-related macular degeneration (wet AMD) did not meet the primary goal of matching the visual improvement of the standard aflibercept treatment in the LUCIA Phase 3 trial. However, DURAVYU demon...

Company Fundamentals
Neutral
1 hour ago
Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...

Market News
Bullish
1 hour ago
Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics announced that Mark Vale, former UPS president and current CEO of Transportation Insight, will join its board and chair the audit committee after its merger with Churchill Capital Corp XI. Vale's extensive experience in global logist...

Company Fundamentals
Bullish
1 hour ago
JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash, Pakistan's leading digital financial services platform, won the Silver Award in the Banking – InsurTech category at Money20/20 USA 2026 for its health-protection platform Sehat+. This platform provides affordable health insurance to Pakista...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App